Amid Regeneron's emergency use bid, former FDA chief says US 'too late' on mass manufacture of COVID-19 antibodies

Days removed from its star turn in President Donald Trump's COVID-19 treatment, Regeneron's antibody cocktail could be on the fast track to an emergency approval. But if it gets there, will there be enough supply to meet this year's demand? That boat's already sailed, a former FDA chief warned.